公开(公告)号：US20230029594A1

公开(公告)日：2023-02-02

申请号：US17788524

申请日：2020-12-23

Applicant: OSAKA UNIVERSITY ,  INNATE CELL THERAPY INC.

Inventor： Shizuo AKIRA ,  JOSE CALDEZ MATIAS ,  Nobuo SAKAGUCHI

IPC: C12Q1/02 ,  A61P1/16 ,  C12N15/113 ,  C07K16/40

Abstract: The present invention provides a body fat reducing agent comprising a Regnase-1 inhibitor as an active ingredient, and a method for screening for a substance capable of reducing body fat, the method comprising selecting a substance capable of inhibiting the expression of Regnase-1 or a substance capable of inhibiting the function of Regnase-1. The body fat reducing agent of the present invention is useful for improving metabolic syndrome, and for preventing and/or treating fatty liver disease, including nonalcoholic steatohepatitis (NASH). The screening method of the present invention can be used to identify a useful substance capable of reducing body fat.

公开(公告)号：US20220125891A1

公开(公告)日：2022-04-28

申请号：US15734885

申请日：2019-06-06

Applicant: OSAKA UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Shizuo AKIRA ,  Takashi SATOH ,  Hiroki TANAKA ,  Keiko SAITO ,  Yusuke YAMAGISHI

IPC: A61K38/45 ,  A61K38/17 ,  C07K16/40 ,  C07K7/64 ,  A61P17/06 ,  C12Q1/48 ,  G01N33/573 ,  A61P13/12 ,  A61P17/02 ,  A61P27/02 ,  A61P37/06 ,  A61P25/00

Abstract: The present invention found that, for example, inhibiting phosphorylation of a Ser residue in Regnase-1 is effective in treating and/or preventing diseases. The invention also found that, for example, inhibiting the binding of Regnase-1 with at least one factor selected from the group consisting of TBK1, IKKi, Act-1, IKK, and IRAK is effective in treating and/or preventing diseases.

公开(公告)号：US20250018014A1

公开(公告)日：2025-01-16

申请号：US18753584

申请日：2024-06-25

Applicant: OSAKA UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Shizuo AKIRA ,  Takashi SATOH ,  Hiroki TANAKA ,  Keiko SAITO ,  Yusuke YAMAGISHI

IPC: A61K38/45 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P25/00 ,  A61P27/02 ,  A61P37/06 ,  C07K7/64 ,  C07K16/40 ,  C12Q1/48 ,  G01N33/573

Abstract: The present invention found that, for example, inhibiting phosphorylation of a Ser residue in Regnase-1 is effective in treating and/or preventing diseases. The invention also found that, for example, inhibiting the binding of Regnase-1 with at least one factor selected from the group consisting of TBK1, IKKi, Act-1, IKK, and IRAK is effective in treating and/or preventing diseases.

公开(公告)号：US20160122378A1

公开(公告)日：2016-05-05

申请号：US14895314

申请日：2014-06-04

Applicant: OSAKA UNIVERSITY ,  NIPPON ZENYAKU KOGYO CO., LTD.

Inventor： Shizuo AKIRA ,  Ken ISHII ,  Cevayir COBAN ,  Yoshikatsu IGARI ,  Yasumasa KANO ,  Akina OTSUKI

IPC: C07F15/02 ,  A61K39/39

CPC classification number: C07F15/025 ,  A61K39/39 ,  C07B2200/13 ,  C07D487/22

Abstract: This invention provides a method of preparing a β-hematin crystal comprising a step of heating, the β-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the β-hematin crystal. The β-hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 μm, and it exhibits main peaks characteristics for angles of diffraction (2θ) of 7.4°, 12.2°, 21.6°, and 24.1° in an X-ray diffraction pattern obtained by powder X-ray diffractometry with Cu—Kα rays (with each peak including a plus-minus 0.2° diffraction angle).

Abstract translation: 本发明提供了一种制备“晶体”晶体的方法，其包括加热通过这种方法获得的凝胶晶体的步骤和含有该化合物晶体的疫苗佐剂组合物。 该化合物晶体具有针状形态，其平均粒径为0.6〜1.2μm，其衍射角（2θ）为7.4°，12.2°，21.6°，和 在具有Cu-Kα射线的粉末X射线衍射法（每个峰值包括正负0.2°衍射角）获得的X射线衍射图中为24.1°。

公开(公告)号：US20130266612A1

公开(公告)日：2013-10-10

申请号：US13856002

申请日：2013-04-03

Applicant: NITTO DENKO CORPORATION ,  OSAKA UNIVERSITY

Inventor： Masahiro FUKASAKA ,  Arimichi OKAZAKI ,  Daisuke ASARI ,  Mitsuhiko HORI ,  Shizuo AKIRA ,  Osamu TAKEUCHI

IPC: A61K39/39 ,  A61K39/145

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/575 ,  C12N7/00 ,  C12N2710/00034 ,  C12N2760/16034 ,  C12N2760/16134 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412

Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.

Abstract translation: 提供可用于感染性疾病的预防或治疗剂，有效诱导全身免疫应答或粘膜免疫应答的口服给药的疫苗组合物。 一种用于给予人或动物口腔的疫苗组合物，所述疫苗组合物含有至少一种源自感染性疾病的抗原，以及至少一种选自toll样受体4（TLR4）激动剂 ，一种toll样受体2/6（TLR2 / 6）激动剂和环二核苷酸，或其衍生物或盐。